Head-to-head · WeighScore
Embody vs Midi Health
The verdict
Embody takes it — 76.2/100 to 56.4/100.
Embody grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Embody | Midi Health |
|---|---|---|
| WeighScore | 76.2/100 | 56.4/100 |
| Grade | C | C |
| Scorecard rank | #52 | #414 |
| Semaglutide | $79/mo (all doses, promotional rate, compounded) | Not disclosed |
| Tirzepatide | $129/mo (all doses, promotional rate, compounded) | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #52 · C
Strengths
- Among the lowest flat rates in the compounded segment — $79/mo semaglutide and $129/mo tirzepatide injection at every dose
- Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- Available in all 50 states with no insurance friction
- 24/7 unlimited clinician messaging and dose-adjustment support included
- Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
Where it loses points
- The $79 flat rate relies on an auto-applied promo 'locked forever' — list price in the terms is $199/mo and reviewers allege the lock isn't honored
- Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- Pharmacy partners not publicly named — compounding source transparency is limited
- Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
Graded #414 · C
Strengths
- Available in all 50 states
- Accepts commercial insurance — a differentiator vs cash-pay-only GLP-1 telehealth
- Menopause + metabolic-health focus suits women where GLP-1 efficacy and weight regulation overlap most
- Transparent self-pay visit fees ($250 initial, $150 follow-up); GLP-1 can also be billed through commercial insurance (copay + deductible)
Where it loses points
- Does not accept Medicare, Medicaid, or Medi-Cal
- GLP-1 is prescribed at clinician discretion within a menopause plan, not guaranteed at intake
- Menopause-focused — not the right fit for men or younger women whose main goal is weight loss
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.